This is the authors' abstract. We don't add key points for this paper.
The risk of oncogenesis mediated by vector-induced insertional mutagenesis during therapeutic gene transfer has received much attention in recent years. Any nucleic acid, regardless of how it is delivered, can cause insertional mutagenesis if it integrates into the genome. The two parameters that define this risk are integration site preference and frequency of integration. Recombinant adeno-associated viral (rAAV) vectors have been shown to be safe and efficacious in early gene therapy clinical trials,1,2,3,4 although such vectors do integrate into the genome at a low but measureable rate (0.1 to 1% of transduction events) in animal models.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Valdmanis et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: